SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2021 / Cilt: 46 - Sayı: 5

Better survival associated with successful vitamin D supplementation in non- metastatic breast cancer survivors

Elif İŞBİLEN
Tülay KUŞ
Havva Yeşil CİNKIR
Gökmen AKTAŞ
Ayşegül BÜYÜKBEBECİ
Pages
509–518
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Vitamin D supplementation may play an important role in the response of the received treatments and provide a lower mortality rate and better overall -free survival (OFS) and disease-free survival (DFS) to BC patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: We aimed to clarify whether successful vitamin D supplementation could predict improved sur- vival in breast cancer (BC) survivors after completion of adjuvant treatment.
📊
Key Findings & Data:Materials and Methods: Patients were classified into four groups based on changes of 25(OH)D level during the treatment follow-up.
💡
Conclusion & Impact:Conclusions: Vitamin D supplementation may play an important role in the response of the received treatments and provide a lower mortality rate and better overall -free survival (OFS) and disease-free survival (DFS) to BC patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: We aimed to clarify whether successful vitamin D supplementation could predict improved sur- vival in breast cancer (BC) survivors after completion of adjuvant treatment. Materials and Methods: Patients were classified into four groups based on changes of 25(OH)D level during the treatment follow-up. Log-rank statistics were used to compare survival distributions among groups. ORs and 95% CIs were given for mortality ratios. Results: The risk of death in group II with low 25(OH)D levels was 4.2 times higher than in group I with high 25(OH)D levels. (OR = 4.17 (95% CI = 1.46–11.91), P = 0.008) and the risk of death in group IV whose 25(OH) D levels never increased was 4.3 times higher (OR = 4.29 (95% CI = 1.13–16.3)). According to the log-rank test, life expectancy was significantly higher in group II compared to group I (P = 0.017) and group III (P = 0.001). Group IV had significantly lower survival times than group III (P = 0.021). Conclusions: Vitamin D supplementation may play an important role in the response of the received treatments and provide a lower mortality rate and better overall -free survival (OFS) and disease-free survival (DFS) to BC patients. However, we observed a sign of poorer BC sur- vival still after sufficient vitamin D supplementation

🔖

Cite This Article

İŞBİLEN, E., KUŞ, T., CİNKIR, H. Y., AKTAŞ, G., BÜYÜKBEBECİ, A. (2021). Better survival associated with successful vitamin D supplementation in non- metastatic breast cancer survivors. Türk Biyokimya Dergisi, Cilt: 46 - Sayı: 5, 509–518. https://ajindex.com/articles/402751

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 2016;96:365–408
  2. Zheng Y, Trivedi T, Lin RCY, Fong-Yee C, Nolte R, Manibo J, et al. Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/β-catenin signaling. Bone Res 2017;5:17023
  3. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006;57:234–40
  4. Hii C, Ferrante A. The non-genomic actions of vitamin D. Nutrients 2016;8:135
  5. Fleet J, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012;441:61–76
  6. Min D, Lv XB, Wang X, Zhang B, Meng W, Yu F, et al. Downregulation of miR-302c and miR-520c by 1,25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer 2013;109:723–30
  7. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 2009;19:84–8
  8. Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, et al. Circulating levels of vitamin D and colon and rectal cancer: the physicians’ health study and a meta-analysis of prospective studies. Cancer Prev Res 2011;4:735–43
  9. Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, et al. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. PLoS One 2011;6:e28520
  10. Zhang L, Zou H, Zhao Y, Hu C, Atanda A, Qin X, et al. Association between blood circulating vitamin D and colorectal cancer risk in Asian countries: a systematic review and dose-response meta- analysis. BMJ Open 2019;9:e030513
  11. Fedirko V, Mandle HB, Zhu W, Hughes DJ, Siddiq A, Ferrari P, et al. Vitamin D-related genes, blood vitamin D levels and colorectal cancer risk in Western European populations. Nutrients 2019;11:1954
  12. Deschasaux M, Souberbielle J-C, Latino-Martel P, Charnaux N, Druesne-Pecollo N, Galan P, et al. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Br J Nutr 2015;115:1–10
  13. Sawada N, Inoue M, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, et al. Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested case-control study in Japan: the JPHC study. Eur J Clin Nutr 2017;71:132–6
  14. Ramakrishnan S, Steck SE, Arab L, Zhang H